CAR-T cell therapy for autoimmune diseases
Treatments studied
Part of Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It's designed for people with certain autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's syndrome that are not controlled by standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- You have been diagnosed with one of the autoimmune diseases listed: SLE, systemic sclerosis, ANCA vasculitis, inflammatory myopathy, or Sjögren's syndrome.
- Your disease is active (moderate to severe), and standard treatments haven't worked well enough.
- Your liver, kidneys, and blood counts are within a safe range (your doctor can check).
- You are not pregnant, breastfeeding, or planning to become pregnant during the trial.
- You have not had a serious infection in the last 2 weeks, and you do not have active hepatitis B, C, HIV, or syphilis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called C-CAR168, which uses a patient's own immune cells to target and potentially reset the immune system to treat conditions like multiple sclerosis, lupus, and myasthenia gravis. It's for people whose disease has not improved with standard treatments.
This trial tests a new type of CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells, to reset the immune system in people with severe autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's syndrome. It aims to reduce disease activity and potentially improve quality of life.
This trial tests a new treatment called RD06-05, which uses specially engineered immune cells to target and potentially reset parts of the immune system that are attacking your own body. It is being studied for several autoimmune conditions like lupus, vasculitis, kidney diseases, and more.
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
This trial is testing whether a type of immune cell therapy called CAR-T cells can help people with severe autoimmune diseases that have not improved with standard treatments. It may offer a new option for conditions like lupus, Sjogren's syndrome, or vasculitis when other therapies have failed.
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.